Interstitial lung disease following COVID-19 vaccination: A disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Min-Taek | - |
dc.contributor.author | Lee, Ju Won | - |
dc.contributor.author | Lee, Hyeon Ji | - |
dc.contributor.author | Lee, Jong-Min | - |
dc.contributor.author | Choi, Jae Chol | - |
dc.contributor.author | Gu, Kang-Mo | - |
dc.contributor.author | Jung, Sun-Young | - |
dc.date.accessioned | 2024-01-08T06:32:50Z | - |
dc.date.available | 2024-01-08T06:32:50Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 2052-4439 | - |
dc.identifier.issn | 2052-4439 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69371 | - |
dc.description.abstract | Background and objective Despite several case reports, population-based studies on interstitial lung disease (ILD) following COVID-19 vaccination are lacking. Given the unprecedented safety issue of COVID-19 vaccination, it is important to assess the worldwide patterns of ILD following COVID-19 vaccination. This study aimed to investigate the signals of COVID-19 vaccine-associated ILD compared with other vaccinations using disproportionality analysis. Methods We analysed the VigiBase database during the period between 13 December 2020 and 26 January 2023. We adopted the case/non-case approach to assess the disproportionality signal of ILD for COVID-19 vaccines via 1:10 matching by age and sex. We compared COVID-19 vaccines with all other vaccines as the reference group. Results Among 1 233 969 vaccine-related reports, 679 were reported for ILD. The majority of ILD cases were related to tozinameran (376 reports, 55.4%), Vaxzevria (129 reports, 19.0%) and elasomeran (78 reports, 11.5%). The reporting OR of ILD following COVID-19 vaccination was 0.86 (95% CI 0.64 to 1.15) compared with all other vaccines. Conclusion No significant signal of disproportionate reporting of ILD was observed for COVID-19 vaccines compared with all other vaccines. Moreover, when compared with the influenza vaccines that are known to cause ILD, no signal was observed. This study results might help decision-making on the subsequent COVID-19 vaccination strategy of ILD. Further large and prospective studies are required for more conclusive evidence. © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMJ Publishing Group | - |
dc.title | Interstitial lung disease following COVID-19 vaccination: A disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1136/bmjresp-2023-001992 | - |
dc.identifier.bibliographicCitation | BMJ Open Respiratory Research, v.10, no.1 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001127789300008 | - |
dc.identifier.scopusid | 2-s2.0-85179641855 | - |
dc.citation.number | 1 | - |
dc.citation.title | BMJ Open Respiratory Research | - |
dc.citation.volume | 10 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | drug induced lung disease | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.